SCHEMBL22093062

SCHEMBL22093062

O=C(O)c1ccc(Cl)c(Cl)c1Nc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPT P10636 2/20 0.51
CLCN2 P51788 8/20 0.48
GFER P55789 1/20 0.47
NGLY1 Q96IV0 1/20 0.47
TSHR P16473 1/20 0.47
AKR1C3 P42330 2/20 0.47
AKR1C2 P52895 2/20 0.47
TTR P02766 2/20 0.47
AKR1B10 O60218 1/20 0.47
ABCB11 O95342 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
CHRM1 P11229 1/20 0.47
FABP2 P12104 1/20 0.47
RXRA P19793 1/20 0.47
TBXA2R P21731 1/20 0.47
NR4A1 P22736 1/20 0.47
PTGS1 P23219 1/20 0.47
PDE4A P27815 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31145465 1.00 MEN1 (0.51) MEN1KMT2AMAPTCLCN2GFER
SCHEMBL22093629 0.87 CXCR2 (0.50) MEN1KMT2AMAPTCLCN2GFER
SCHEMBL31145441 0.87 CXCR2 (0.50) MEN1KMT2AMAPTCLCN2GFER
SCHEMBL28286415 0.83 MEN1 (0.51) MEN1KMT2AMAPTCLCN2GFER
SCHEMBL2406195 0.83 MAPT (0.62) MEN1KMT2AMAPTGFERNGLY1
SCHEMBL11543358 0.81 ALDH1A1 (0.57) MEN1KMT2AMAPTCLCN2TSHR
SCHEMBL21027403 0.80 MPO (0.46) MEN1KMT2ACLCN2AKR1C3AKR1C2
SCHEMBL21027986 0.80 AKR1C3 (0.43) MEN1KMT2AMAPTCLCN2GFER
SCHEMBL11060535 0.79 MAPT (0.47) MEN1KMT2AMAPTCLCN2GFER
SCHEMBL8285642 0.77 CXCR2 (0.60) MEN1KMT2AMAPTCLCN2GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 US disclosed
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2022-04-07 US disclosed
EP-3894396-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Ideaya Biosciences, Inc. (US) 2021-10-20 EP disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 US disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 US disclosed
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-08-10 US disclosed
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-08-10 US disclosed
CN-113166078-A 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2021-07-23 CN disclosed
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-06-29 US disclosed
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-06-29 US disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 WO disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A MEN1 1381/4885KMT2A 102/4885MAPT 1760/4885
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A MEN1 1381/4885KMT2A 102/4885MAPT 1760/4885
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A MEN1 1381/4885KMT2A 102/4885MAPT 1760/4885
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2B, MAT2A, MAT1A MEN1 1381/4885KMT2A 102/4885MAPT 1760/4885
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A MEN1 1381/4885KMT2A 102/4885MAPT 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.